Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep. That's a revolving line of credit. Fife's loan gets one because it's paid down n stocks. If you just pay off a loan in cash, you update quarterly. Especially one that bore no interest. Where does it say they need an 8k? What they would need one for is giving him enough stock to trigger the limit.
Wouldn't be one. Don't need it
Recknor 's compensation at a large pharma as a director would pretty well parallel what he was being compensated as a VP with Cytodyn. There is no way they could bring him in as a VP with his experience level and they couldn't offer him that much of a better package. PIs come on board at the director level.
120 days after warrants issued. As you said, there has been no 8k saying shares or warrants have been issued. It would be 4 months after that
Show me where they have to put course of business paymentsin an 8k
Don't need one. They put several out for money raises. They don't need one for writing a check. And, no one buying a drug is going to let it go over a few million dollars. With that line of thinking, you are not looking at a hole in the ground
Cool. Looks like they may have gotten an extra dose of leronlimab in part 2 because they didn't have the placebo run in. It could account for why 359 mg hit stat sig and 700 mg missed it. They could have been on the cusp of response. That would be the KISS theory to test first before getting lost in the weeds of dosing
I agree
I'm still gonna go with someone buying leronlimab would take Recknor, but, in order to do so, he'd need to be a director level. They're not going to keep Cytodyn as a subsidiary imo. They're essentially buying a drug, but it's Cytodyn's only drug.
I thought he was part of the last group. I'd check, but it seems like a silly thing to focus on. He mentioned it in a reply to something I wrote as well. You could speculate about a lot of things. He could have gotten the director position so he could transition to a company buying us out. They wouldn't necessarily take executives, but would take directors. The shares instead of cash could be a way to soften the blow for the execs.
You don't remember that he got a new position then?
Could be he needs the cash for a mortgage payment or that he's in London and buy the time the paperwork was done, he was asleep
Looks like the reason they may have settled with Pestell was to make sure he wouldn't try to make any claims against their patent submitted on 26May 2022. Now the settlement looks cheap and makes sense.
Timing makes sense for the last time Cytodyn had to make a payment to him on the loan - February 2022. I wondered what happened there
Honestly, abandoning va trademark name could be construed as a sign of big pharma influence. Marketing bout a lot of time and effort into those. I doubt Cytodyn did that.
Didn't we already know last year that they weren't going to go with that trademark? It's misleading anyway since it's not technically an antiviral
The really important thing is that it doesn't sequester in the body and doesn't need to be slowly weaned. The most important information that came out of the study and it was completely ignored. We're now in clinical hold IMO because no one has really thought through how that information allays other FDA's safety concerns which understandably came up when experts started telling the FDA that leronlimab's MOA isn't what you thought but it's ok because the real MOS will help Covid patients. That's why I think the FDA wanted the 2 doses.
Really? You're going at this over whether or not the execs are getting minimum wage in addition to stock? It sounded to me like they were getting enough to cover taxes which would be more than that.
Pfizer made an equity investment in Akero at 9.90 a share for $25 million. It was announced today at the end of the conference Akero attended, but that doesn't mean that was when the investment was made or agreed to. It likely just had to wait for the conference to be over so they wouldn't steal anyone's thunder
Yep. Cuz they can't say I quit or file for bankruptcy protection. I believe Aaron that they already covered the loan from Welch for the bond. There haven't been any 8ks since February about Fife loans and none about having to work out terms with Samsung. They update their share count on an almost daily basis and it was still at 719 million yesterday which was about where they were at the time of their last 8k. The one thing that's changed is that they don't seem to be selling more shares most days to raise cash.
I decided to clink the link for EASL after clicking the link in your message that had nothing to do with EASL
EASL started in 1966
The company in your link 2007
EASL has offices in Switzerland and Belgium and calls itself the Home of Heptology
The company in your link does not
BTW, Novo Nordisk just tweeted on EASL's website 20 minutes ago that they will be at the conference next week to discuss all things NASH.
They didn't tweet on the website you linked
Finally, first come, first serve just means that they won't kick anyone out of the program bfor a late breaking poster. It's called manners and forced people to get on the ball and submit their stuff if they want a place. You can't say no to a big guy unless you're one yourself
So, the haplotype that overproduces CCR5 responded the absolute best to leronlimab. I'd say that's proof of concept.
2.5 million shares short today. That was 60% of trades. Only 50k new shares were borrowed
Not buying, but I think someone got it right on Stocktwits. It's twice monthly awards. It's their salary and they aren't selling shares.
Fintel has 3 million shares sold short today. Watch your stop losses. They're going to try to buy back cheaper. Set up a phone alert instead
The NDA was put in place in January. Before the price tanked and before GoodRx paid almost as much for a fraction of the company
Someone did the math and the share count went up by 140k. I do wonder if it was needed for failure to deliver shares and if this hedge fund sold theirs for it as well when the price hit $29 and $22; overnight two days in a row after the announcement.
13g just released. A fund just sold about 400k of their 500k+ shares. Not sure if they are allowed to get a premium price after hours, but, if so that might have been it. EW needs 50% of shares. They may have negotiated a good price for theirs. It does mean fewer shares for shorts. If they didn't sell the remaining 160+k shares because they were on loan, shorty may be in trouble.
I'm pretty sure someone more competent at the till of the Titanic would have made a difference.
He's got an MBA. That's why he was hired. I can't explain why engineers like to get MBAs. It may be due to marketability. The engineering degree is highly marketable as a bachelor's degree and MBA for masters. It could be as simple as lateral , goal oriented thinkers. We can use that.
An abundance of caution following that weird thing they got from the FDA about not saying that your investigational drug has benefits because people might believe you and buy it even though it isn't on the market yet.
It's heartgard. It was originally for dogs I believe. I remember we always knew when they were making a batch at the Rahway site. It had a sulphur like smell to it and it always seemed to go off at lunchtime. I'd have to walk past it on my way to the cafeteria. My friends were with the animal health group doing flea research, so they were right nearby. It was worse for them. They were pretty n a trailer and didn't even have negative pressure airflow
Merck donated Ivermectin to Africa for years to help fight river blindness. They've been giving it to people since at least the 90s
Unless, of course, he signed a contract before performing the duties of a contract CFO. I know many places use that instead of a LinkedIn profile to determine what services someone is performing and how to pay them.
Donald Trump or someone in his organization likely knew about leronlimab back when it was Pro-140. They were planning to build an apartment tower next to the Ritz Carlton one in White Plains back around 2005 or 2006. Those condos were going for 750 k and higher. No way they didn't do an analysis of the local businesses. Regeneron and Progenics were in the same building in Tarrytown- next town over. Some of the big guys from Merck we're invested in Regeneron. Trump Organization would have known where the potential future millionaires were and what they were working on. The judge from Fox ran for a judgeship or DA or something when I was living down the street from where those towers were going up in White Plains. Dr. Siegel did a segment on leronlimab for Fox, I believe. It would have rang a bell with someone. No way it didn't
And, yet, he knew about them.
Donald Trump couldn't get it. Cytodyn wanted to offer it to him, Otto Yang was apparently giving it to celebrities with good outcome. I can't imagine Trump didn't want to try it out for himself, but he got the other stuff instead. If the military docs had felt confident in it's safety, he would have had it. They needed to know it fell off as quickly as it went on. Otherwise, they would not have been able to control the downward spiral of the immune system once it started. It's a strong evolutionary process meant to protect the species from anihilation. We know for sure now and good doctors instincts told them then that it was ok, but the FDA has to worry about the infusion nurses at a site in Florida or the pharmacy tech in Alabama being able to give it to the general public. I understand in retrospect why they weren't quite there with Cytodyn in the summer of 2020.
They had safety data in immunocompromised patients, not overactive immune patients. Totally different patient group. What helps one could theoretically kill the other.
The double edged sword for that would be that if the FDA realized that, it wouldn't give them a clear read on safety. Needed the lab results for that.
Our problem imo was the skill level of the teams who wanted leronlimab. Look at the 90 day survival from RLFTF's drug. It was 36 vs 37. And that was being run by NIH and at a time when teams had learned how to treat patients and had more options. We were just n the 80s at the craziest time in the pandemic, but so was placebo. Our docs were on the cutting edge of treatment.